sa55
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 9, 2023 (NCT05675943)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - sars-cov-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06042764 | Phase 2 | Aug 31, 2023 | China National Pharmaceutical Group, Jiao Tong University |
| NCT06050460 | Phase 1 | Jun 15, 2023 | Capital Medical University, China National Pharmaceutical Group |
| NCT06048393 | Phase 1 | May 31, 2023 | Capital Medical University, China National Pharmaceutical Group |
| NCT05675943 | N/A | Jan 9, 2023 | Beijing Boren Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China National Pharmaceutical Group | For profit | 3 | 3 | 2 | 2023 |
| Capital Medical University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Beijing Boren Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1